| Objective:1.Clinical case data were collected to compare the short-term efficacy and adverse effects of Pembrolizumab and Nivolumab in patients with advanced NSCLC,and to further analyze the factors influencing the short-term efficacy(including age,sex,smoking,pathologic type,and PD-L1 expression).2.Immune-related adverse reactions were counted to provide reference for rational drug use in clinic.Methods:A total of 60 cases of Nivolumab and Pembrolizumab undergoing treatment between January 2019 and January 2022 were collected from the undergraduate patient base by reviewing inpatient records,outpatient records,and telephone follow-up.Age,sex,pathologic type,smoking history,PD-L1 expression,MSS,TMB,HER-2 expression,efficacy evaluation,PFS,OS,and adverse events were recorded in 50 patients in the Pembrolizumab group and 10 in the Nivolumab group.Results:Among the 107 patients who were all treated with Pembrolizumab,50 patients were collected after excluding neoadjuvant therapy,adjuvant therapy and lost follow-up.Among patients with advanced NSCLC,the mPFS was 8.0 months in the final 50 patients in the Pembrolizumab group and 4.05 months in the 10 patients in the Nivolumab group.Immunerelated adverse reactions occurred in 8 patients(16%)in the Pembrolizumab b group,including 1patient with hypothyroidism(G3),3 patients with immune-related pneumonia(G2,G3,G4),3patients with fatigue(G1,G2,G2),and 1 patient with rash and itching(G2).The ECOG score of 10 patients in the Nivolumab group was 0-2,the median age was 69 years,and the m PFS was 4.05 months.Ir AEs were not recorded in all 10 patients.Conclusions:1.In patients with advanced NSCLC,the median PFS was 8.0 months in the Pembrolizumabgroup and 4.05 months in the Nivolumab group..2.Pd-L1 expression level is correlated with prognosis,and patients with high PD-L1 expression have better efficacy than those with low PD-L1 expression.3.The incidence of immune-related adverse reactions was low and the completeness was good. |
PDF Full Text Request